346 Index Name Paper ref. Name Paper ref. Lazdunski, M FC03.4.2 Lazo-Langner, A Tue 301 Le Couteur, D FC13.2.6, Mon 392, FC13.1.6 Le Gall, C Mon 263 Le Grand, B Tue 183, Tue 170, Tue 171, Tue 172 le Maire, A FC18.3.5 Le, O Tue 396 Leach, K Wed 043, Wed 089, Thu 041 Leadbeater, PDM Thu 200 Leal, LK Mon 299 Leal, N Wed 111 Leánez, S Thu 042, Wed 059 Lebedeva, E Wed 148 Lecomte, C Tue 092 Ledent, C Thu 057 Ledo, F Mon 254 LeducC, N Thu 024 Lee, A Tue 460 Lee, AJ Tue 109 Lee, DH Mon 013 Lee, D Tue 349 Lee, F Wed 122, Wed 121, Wed 120 Lee, G-S Thu 385 Lee, HC Thu 090 Lee, H-J Wed 035 Lee, H-K Wed 427 Lee, MG Tue 046, Mon 068, Mon 062 Lee, M-H Wed 383 Lee, MYK Thu 270 Lee, S Mon 034, Lee, S-C Tue 335 Lee, S-Y Tue 350 Lee, SH Tue 334 Lee, S-J Thu 034 Lee, SS Tue 157, Tue 352, Tue 351 Lee, S-J Tue 352, Tue 351 Lee, S-Y Mon 049, Mon 069, Mon 065, Mon 066, Mon 358, Mon 359, Tue 043, Tue 044, Tue 073, Tue 160, Tue 161, Tue 162, Tue 323, Tue 324, Tue 331, Tue 332, Tue 333, Tue 335, Wed 142, Wed 143 Lee, TJF Wed 286, Thu 090, Thu 362 Lee, VHL FC02.4.6, Tue 140 Lee, W-H Mon 104 Lee, W-S Wed 449 Lee, W-Y Tue 229 Lee, WYW Thu 389, Thu 381 Lee, Y Mon 033 Lee, Y-C Wed 286 Lee, YJ Mon 029, Mon 226, Mon 013, Tue 349, Thu 418 Leeb-Lundberg, F Thu 047 Leeder, P Wed 285 Leeder, SJ FC13.3.3 Leeds, C Wed 432 Lees, KR FC15.1.6 Lees, P Tue 191 Leeya, Y Wed 375 Leftheriotis, G Mon 148 Lehmann-Horn, F FC12.2.3 Lehri, S Mon 469 Lehtimäki, L Mon 328 Lehto, V-P Thu 170 Lei, Saobo Wed 090 Lei, SH Tue 348 Lei, SL Mon 451 Lei, T Thu 377 Lei, Y Tue 298 Leirisalo-Repo, M FC09.2.5 Leiro, J Wed 359 Leitão, R Mon 298 Lekhooa, Makhotso R Wed 389, Wed 390, Wed 391 Lello, J Wed 392 Lelong-Boulouard, V Thu 173, Mon 362 Lemasson, I FC11.3.6 Lemière, C FC04.1.5 Lemkens, P Thu 251, Thu 221 Lemkens, P Wed 287 Lemmer, B W07.1 Lemos, FO Wed 302 Lemos, M Wed 231, Wed 341 Lendak, D Mon 115 Lennard, L Mon 351, Tue 353 Leo, CH Wed 288, Wed 289 León, O Thu 358 Leone, S Mon 105, Wed 329, Wed 434 Leong, CF Thu 380 León-Molina, H Mon 019 Leopardi, R FC17.5.4 Lepikkö, V Mon 060 Lepine, JP FC01.4.4 Lepine, -J-P Wed 191 Leppänen, T FC09.5.4, Tue 247 Leppee, M Mon 127 Leppiniemi, J Thu 223 Leprán, A Thu 307 Lepran, I Tue 157 Lerner, F Mon 030 Leskinen, H Tue 166 Letienne, R Tue 170, Tue 171, Tue 172 Letierce, A W02.2.6 Lett, K Tue 063 Lettfuss, NY Mon 463 Leung, GPH Wed 091 Thu 255 Leung, JYT Mon 184 Leung, PC Wed 345 Leung, RYH Mon 271, Mon 159 Leung, SWS FC15.2.6, Tue 157, Wed 091, Wed 290, Wed 388 Leurs, R Wed 086, Thu 085, Thu 060 Leutenegger, D Wed 392 Levälampi, T FC09.2.5 Levanov, A Tue 129 Lévesque, D FC17.4.6, Wed 443 Lévi, F FC07.1.3, FC07.2.4, W07.2 Levonen, A-L Wed 448 Levy, FO FC06.3.3, Wed 026 Levy-Cooperman, N Wed 193 Levykh, A Tue 354 Leweke, M FC17.2.2 Lewis, RS FC12.5.2 Leybaert, L Thu 237 Leymarie, F FC04.3.5 Li, BL Tue 299
Name Paper ref. Name Paper ref. Li, DJ Mon 322 Li, D-L Tue 187, Tue 186, Tue 159 Li, F FC14.4.6, Thu 182, Thu 185 Li, G Mon 264, Thu 196 Li, G-R FC12.3.5 Li, H FC15.4.3, W04.3.3, W30.1, W30.4, Tue 163, Thu 340 Li, J FC12.2.5, FC14.5.4, Mon 323, Mon 457, Mon 466, Tue 117, Tue 299, Wed 034, Wed 417, Thu 195, Thu 171, Thu 340 Li, J-R Wed 403 Li, K Tue 403 Li, KX Mon 032 Li, L Tue 158, Thu 370, Thu 370, Thu 378 Li, M Wed 150 Li, M-J Wed 403 Li, N FC16.3.5, Tue 355, Thu 296 Li, P Tue 412, Mon 408, Wed 327, Mon 469 Li, Q Tue 138, Mon 458 Mon 330, FC16.4.5 Li, QY Tue 036 Li, R FC14.3.5 Li, RWS Thu 255 Li, S Tue 401, Thu 276, Tue 365 Li, T Mon 056 Li, TT Wed 039 Li, W Thu 377 Li, WD Thu 295 Li, W-L Tue 393 Li, X Mon 056, Mon 092, Mon 251, Tue 069, Tue 070, Tue 307, Wed 182, Thu 195, Thu 299, Thu 314, Thu 377 Li, X-Y Mon 031 Li, X-J Tue 426, Thu 076, Thu 103 Li, X Tue 418 Li, X-Z Mon 209 Li, Y Tue 069, Tue 070, Tue 260, Tue 294, Mon 310 Li, Y Mon 185 Li, Y Mon 032 Li, Y Thu 296, FC16.3.5 Li, Y-F FC14.4.6 Li, Y-H Wed 262 Li, YJ Mon 469 Li, Z Thu 372, Thu 020 Li, ZX Wed 291 Lia, S Thu 279 Liam, CK Tue 254 Lian, LH Wed 431 Liang, A Wed 392 Liang, CF YI.06, Mon 324 Liang, HY Wed 039 Liang, J-H Thu 172 Liang, L Thu 197 Liang, M Mon 228 Liao, H-T Wed 035 Liao, M-H Thu 283, Wed 222 Liao, Y-Y Wed 035 Liao, Z Mon 210, Wed 362, Wed 258, FC06.4.6, Wed 366 Liapi, C Tue 381, Thu 431 Lichtenstein, L FC18.2.5 Liddle, C W06.3 Liem-Moolenaar, M FC17.3.5 Liepinsh, E Tue 141, Thu 189 Lignot-Maleyran, S FC04.2.6, Mon 140, Mon 141 Likic, R FC01.3.7, Mon 373 Tue 328, Mon 135 Liley, H Thu 011 Lilic, R Wed 435 Lilleyman, J Tue 353 Lim, AL Wed 428 Lim, LA Mon 013, Mon 033, Mon 226, Tue 349, Thu 418 Lim, SL Mon 184 Lima, C Mon 398 Lima, L Mon 292 Lima, LM Thu 212 Lima, TMA Thu 355 Lima, TS Wed 332 Lima-Júnior, RCP Tue 255 Lima-Landman, MTR Thu 355 Limas Nzouzi, N Tue 040 Liminana, P Wed 244 Lin, AHY Wed 091 Lin, AM-Y Mon 325 Lin, C Wed 336, Thu 340 Lin, C-H Mon 326 Lin, C-L Mon 319 Lin, C-Y FC17.1.5, Wed 326 Lin, G Tue 401, Thu 296, FC16.3.5 Lin, H-H Tue 374 Lin, H-H Thu 198 Lin, J Thu 445 Lin, K-M Wed 430 Lin, L Tue 441, Tue 094 Lin, M Mon 310 Lin, W-W Mon 327 Lin, Y-C Thu 373 Lin, ZB FC16.2.1, Thu 295 Lind, U Wed 092 Lindemalm, S Wed 008 Linden, AM Wed 393 Linden, A-M Thu 409 Linden, H W10.2 Lindh, J Mon 122 Lindholm, M Tue 247 Lindhorst, T Tue 151 Lindquist, L FC01.4.7, Mon 018 Ling, B Tue 094, Thu 083 Lingam, PRVS W03.2 Lingueglia, E FC03.1.1 Linkosalo, L Mon 328 Linnet, J FC17.1.2 Lionnais-Couvreur, S Tue 289, Tue 290 Lipnik-Stangelj, M Wed 178 Lirussi, F Tue 289, Tue 290 Lisby, M Tue 356, Tue 357, Tue 358 Little, C W03.7 Litvin, A Tue 150 Litvinov, D Tue 106 Litvinova, SA Mon 422 Index 347
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299: FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor